To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for ovarian cancer, fallopian tube cancer or primary peritoneal cancer
 
Status Proposed
Process STA 2018
ID number 1652

Project Team

Project lead Thomas Feist

Email enquiries


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance